NYSE American - Delayed Quote USD

China Pharma Holdings, Inc. (CPHI)

2.1600
-0.0600
(-2.70%)
At close: May 19 at 3:59:54 PM EDT
2.1600
0.00
(0.00%)
Pre-Market: 7:44:10 AM EDT
Loading Chart for CPHI
  • Previous Close 2.2200
  • Open 2.2500
  • Bid 1.8000 x 800
  • Ask 2.3400 x 1200
  • Day's Range 2.1300 - 2.2300
  • 52 Week Range 1.2000 - 3.4000
  • Volume 5,244
  • Avg. Volume 105,884
  • Market Cap (intraday) 7.046M
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) --
  • EPS (TTM) -2.2200
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

China Pharma Holdings, Inc. develops, manufactures, and markets pharmaceutical products for human use in the People's Republic of China. The company provides products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate injection to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Ozagrel Sodium to treat acute thrombotic cerebral infarction and dyskinesia; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection for edema diseases, hypertension, acute renal failure, hyperkalemia, hypercalcemia, and acute drug poisoning; and Candesartan for hypertension. It offers Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Andrographolide for sore throat caused by upper respiratory tract infection; Clarithromycin granules and capsules; and Naproxen Sodium and Pseudophedrine Hydrochlorida sustained release tablets. It offers Hepatocyte growth-promoting factors, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. Additionally, the company provides Vitamin B6 injection; Granisetron Hydrochloride injection for nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors; Noni Enzyme, a food supplement; sanitizers; and masks. It supplies its products to hospitals and OTC pharmacies through provincial and municipal pharmaceutical logistics companies. The company is based in Haikou, the People's Republic of China.

www.chinapharmaholdings.com

224

Full Time Employees

December 31

Fiscal Year Ends

Recent News: CPHI

View More

Performance Overview: CPHI

Trailing total returns as of 5/19/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

CPHI
6.09%
S&P 500 (^GSPC)
1.39%

1-Year Return

CPHI
34.55%
S&P 500 (^GSPC)
12.45%

3-Year Return

CPHI
98.27%
S&P 500 (^GSPC)
52.88%

5-Year Return

CPHI
99.04%
S&P 500 (^GSPC)
104.03%

Compare To: CPHI

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: CPHI

View More

Valuation Measures

Annual
As of 5/19/2025
  • Market Cap

    7.05M

  • Enterprise Value

    10.14M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    1.12

  • Price/Book (mrq)

    1.01

  • Enterprise Value/Revenue

    2.36

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -106.30%

  • Return on Assets (ttm)

    -18.22%

  • Return on Equity (ttm)

    -59.83%

  • Revenue (ttm)

    4.3M

  • Net Income Avi to Common (ttm)

    -4.57M

  • Diluted EPS (ttm)

    -2.2200

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    412.69k

  • Total Debt/Equity (mrq)

    50.31%

  • Levered Free Cash Flow (ttm)

    847.51k

Research Analysis: CPHI

View More

Company Insights: CPHI

Research Reports: CPHI

View More

People Also Watch